Literature DB >> 33832291

Investigation into molecular mechanisms and high-frequency core TCM for pulmonary fibrosis secondary to COVID-19 based on network pharmacology and data mining.

Mei-Xiang Yu1, Xin Song2, Xiao-Qin Ma1, Chen-Xia Hao1, Jing-Jing Huang3, Wan-Hua Yang4.   

Abstract

BACKGROUND: The complication, pulmonary fibrosis (PF) secondary to COVID-19, may have a second wave of late mortality, given the huge number of individuals infected by COVID-19. However, the molecular mechanisms of PF secondary to COVID-19 haven't been fully elucidated, making the identification of novel strategies for targeted therapy challenging. This study aimed to systematically identify the molecular mechanisms and high-frequency core traditional Chinese medicine (TCM) targeting PF secondary to COVID-19 through network pharmacology and data mining.
METHODS: The molecular mechanisms of PF secondary to COVID-19 were identified by mapping the COVID-19 differentially expressed gene and known targets associated with PF, protein-protein interactions network analysis, and enrichment pathway analysis; then the high-frequency core TCM targeting PF secondary to COVID-19 were identified by data mining and "Key targets related to PF secondary to COVID-19 - Ingredients" and "Key ingredients-key herbs" network analysis; and last we validated the interaction between the key ingredients and key targets by molecular docking.
RESULTS: The molecular mechanisms of PF secondary to COVID-19 were mainly related to tumor necrosis factor (TNF) signaling pathway, cytokine-cytokine receptor interaction pathway, and NF-κB signaling pathway. Among these, cytokines interleukin 6 (IL-6), TNF, and IL-1β were identified as the key targets associated with PF secondary to COVID-19. The high-frequency core TCM targeting these key targets were identified, including ingredients of quercetin, epigallocatechin-3-gallate, emodin, triptolide, resveratrol, and herb of Polygonum cuspidatum. Finally, our results were validated by quercetin and resveratrol both well docked to IL-6, TNF, and IL-1β protein, with the estimated docking energy <0 kcal/mol.
CONCLUSIONS: This study identified the cytokines-related molecular mechanisms of PF secondary to COVID-19, and the high-frequency core TCM against PF by targeting IL-6, TNF, and IL-1β. Which provides new ideas for the discovery of small molecular compounds with potential therapeutic effects on PF secondary to COVID-19.

Entities:  

Keywords:  Pulmonary fibrosis (PF) secondary to COVID-19; data mining; high-frequency core traditional Chinese medicine (TCM) therapy; molecular mechanisms; network pharmacology

Year:  2021        PMID: 33832291     DOI: 10.21037/apm-20-1384

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  5 in total

Review 1.  Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review.

Authors:  Xiaomin Kang; Linlin Jiang; Yuqing Zhang; Yuehong Zhang; Xuedong An; Liyun Duan; Cunqing Yang; Rongrong Zhou; Yingying Duan; Yuting Sun; Fengmei Lian
Journal:  Chin Med       Date:  2022-02-28       Impact factor: 5.455

Review 2.  Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review.

Authors:  Laura Bergantini; Alessandro Mainardi; Miriana d'Alessandro; Paolo Cameli; David Bennett; Elena Bargagli; Piersante Sestini
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

3.  Assessment of pulmonary infectious disease treatment with Mongolian medicine formulae based on data mining, network pharmacology and molecular docking.

Authors:  Baochang Zhou; Zhanhong Qian; Qinyu Li; Yuan Gao; Minhui Li
Journal:  Chin Herb Med       Date:  2022-07-22

4.  Association of TNF-α, TGF-β1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19.

Authors:  Daniel Maranatha; Helmia Hasan; Arief Bakhtiar; Anita Widyoningroem
Journal:  J Infect Public Health       Date:  2022-08-24       Impact factor: 7.537

5.  Japanese Knotweed Rhizome Bark Extract Inhibits Live SARS-CoV-2 In Vitro.

Authors:  Urška Jug; Katerina Naumoska; Tadej Malovrh
Journal:  Bioengineering (Basel)       Date:  2022-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.